Convergent Science Cancer Consortium
The CSCC is establishing a scalable research infrastructure to demonstrate how convergent science research will address the gaps in cancer care.
Liquid Biopsy Research Laboratory (LBRL)
This Liquid Biopsy Research Laboratory (LBRL) will address specific unmet clinical needs in the early assessment of cancer by developing and validating multi-analyte liquid biopsy (LBx) technologies.
Convergent Science Virtual Cancer Center
The CSVCC is a convergent approach to cancer research that combines advances from diverse scientific disciplines to improve outcomes for patients. The program provides personalized mentorship, support, and funding to 15 early-career scientists studying cancer.
Multiple Myeloma
The CSI multiple myeloma (MM) program aims to develop a blood-based liquid biopsy to detect disease progression and potential relapse. MM is a progressive leukemic disease originating in the bone marrow from the monoclonal expansion of plasma cells. A blood liquid biopsy assay could provide a routine, accessible method for disease staging and monitoring.
Cell-Based Therapeutics
CAR-T and TCR therapies represent cutting-edge advancements in cell-based cancer treatments, offering new hope for patients with certain types of cancer.
